Viral peptide–HLA complex

A **viral peptide–HLA complex** refers to a protein complex formed when a viral peptide (short amino acid sequence derived from a virus) is presented on the cell surface, bound within the peptide-binding groove of a human leukocyte antigen (HLA, a type of major histocompatibility complex or MHC) molecule. This complex is critical for immune surveillance, as it is recognized by T cell receptors on cytotoxic T lymphocytes, allowing the immune system to detect and destroy virus-infected cells. The **HLA molecule** has a highly polymorphic, deep binding groove accommodating viral peptides typically 8–10 amino acids in length, although shorter or longer peptides can sometimes interact[1][4]. The interaction is central to T cell recognition and constitutes the molecular basis of T cell-mediated immunity to viruses, as well as immune escape and tolerance[1][5][6]. Therapeutically, these complexes are direct or indirect targets of cutting-edge immunotherapies, including engineered T cells (such as TCR-T therapies) and antibody-like agents, especially in infectious disease and cancer contexts. There are safety considerations regarding specificity and potential immunopathology due to the vast polymorphism in HLA molecules and the broad diversity of presented peptides[2][6].

Other names

peptide–HLA complexpeptide–major histocompatibility complex (MHC) complexpHLA complexpeptide–MHC complex

Drug binds to the viral peptide–HLA complex and blocks or modifies T cell receptor recognition, thereby altering immune activation against infected or malignant cells. Engineered T cells or antibodies recognize specific viral peptide–HLA complexes, leading to targeted cell killing.